Dividends & Income
To screen ETFs by asset class, performance, yield and more, check out the
This user currently has no profile.
Former sellside biotech analyst (6 yrs); Wall Street Journal Allstar list for Stockpicking, 1999; former medical technology hedge fund manager (2 yrs). Worked in the biotech sector (7 yrs), Stanford Medical Center (2 yrs). BS degrees in biology and biochemistry, MBA. Full-time investor with emphasis on biotech stocks and options.
Options, Stocks - long, Stocks - short, Tech stocks
Currently, there is no company profile for tothman.
Currently, there are no blog details for tothman.
Currently, there are no book details for tothman.
. Still trying to figure out why no one is discussing the ethical considerations of continuing the LIGHT study.
Mar 3, 2015
Here is a link to an intere...
Orexigen's Cardiovascular Safety Data Is A Brea...
Everyone keeps talking abou...
Orexigen Soars: Good News Is Heart Data, Bad Ne...
I'm not sure if I would app...
CA panel deems Sovaldi a "low value" treatment
Why do you believe that Con...
Orexigen Completes Financing Deal
Would you be willing to jus...
Friday's Small Cap Biopharma Catalyst Trade And...
Xignite quote data
© 2015 Seeking Alpha